Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genzyme Tissue Repair

This article was originally published in The Gray Sheet

Executive Summary

Maker of Carticell autologous cultured chondrocytes for treatment of articular cartilage damage would gain up to $66 mil. for continued R&D under a long-term financing plan established by parent company Genzyme Corp. The plan includes an increase from $12 mil. to $50 mil. in GTR's equity line of credit from Genzyme General, another division of Genzyme Corp., as well as the sale of GTR's Framingham, Massachusetts manufacturing facility to Genzyme General for $16 mil. GTR will lease back a portion of the facility for its Neurocell product development program for Parkinson's and Huntington's diseases, while Carticell production will continue at its headquarters facility in Cambridge. Genzyme notes GTR is currently seeking a strategic partner for development of its TGF-Beta2 program for treatment of chronic skin ulcers, which is in Phase II trials...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts